Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Jonathan D. Schwartz
ResearcherPublications, citations & collaboration network
Jonathan D. Schwartz is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 106 works, 9,255 citations, an h-index of 30 and an i10-index of 48.
106
Works
9,255
Citations
30
h-index
48
i10-index
How has Jonathan D. Schwartz's publication output changed over time?
ScholarIQpublication output · 2002–2020
Output grew0% over the shown period — from 1 works in 2002 to 1 in 2020.
1
2
1
2
1
1
1
1
1
200220042008201320142015201620192020
What are the most-cited papers on Jonathan D. Schwartz?
ScholarIQmost cited works
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu
The Lancet Oncology. 20142,486 Citations
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero
The Lancet. 20132,207 CitationsOPEN ACCESS
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo
The Lancet Oncology. 2015846 CitationsOPEN ACCESS
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Abby B. Siegel, E. Cohen, Allyson J. Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul J. Christos, Madhu Mazumdar, E Popa, Robert S. Brown, Shahin Rafii, Jonathan D. Schwartz
Journal of Clinical Oncology. 2008510 CitationsOPEN ACCESS
Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis
Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung, Sukru Emre, Charles M. Miller, Gabriel Gondolesi, Nancy Krieger, Myron Schwartz
S205547219. 2004464 Citations
Related on ScholarIQ
Eternity Bioscience (United States)
Institution
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
Paper
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
Paper
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Paper
Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma
Paper
Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis
Paper